Plexitome Medical has partnered with VEO Ophthalmics to introduce the Plexitome device for the treatment of anterior stromal puncture (ASP).
The advanced device improves precision and consistency in treating Recurrent Corneal Erosion (RCE) and epithelial basement membrane dystrophies (EBMD).
Unlike traditional tools, the Plexitome device employs a 6.2mm diameter disc array featuring about 675 micro-spikes.
The spikes facilitate a controlled and even puncture depth through Bowman’s layer, avoiding visible anterior stromal scarring.
The device can establish up to 3,375 epithelial attachment points through five imprints, aiding corneal recovery and reducing recurrence.
Plexitome Medical founder and chief medical officer Edward Chaum said: “Plexitome represents a significant step forward in the management of corneal disorders, particularly in the optical axis.
“The device was engineered to improve outcomes while eliminating the unpredictability and limitations of manual ASP.
“VEO Ophthalmics has a history of bringing innovative products to market, and we are excited to partner with them for our commercialisation strategy.”
In clinical settings, Plexitome has shown efficacy in penetrating Bowman’s layer via both debrided and loosely intact epithelium.
Unlike traditional ASP methods, the device offers stable epithelial attachments.
Plexitome potentially accelerates healing for large corneal abrasions and reduces the likelihood of recurrence in erosive conditions.
The device, registered as a Class 1 ophthalmic surgical tool by the US Food and Drug Administration (FDA), is designed for single use.
VEO Ophthalmics will oversee the commercial distribution of the Plexitome device.
VEO Ophthalmics CEO Ron Gilliland said: “Plexitome Medical has developed a truly innovative approach to treating RCE and large corneal abrasions.
“Plexitome is sure to reinvent how cornea specialists utilise anterior stromal puncture. We are pleased to work together with Plexitome Medical to bring this new technology to cornea specialists and their patients.”
